{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:29:30Z","timestamp":1753892970131,"version":"3.41.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background of the study<\/jats:title><jats:p>One of the best medical approaches for halting the spread of infectious diseases is vaccination. During the COVID-19 pandemic, healthcare workers (HCWs) were a high-risk population. Due to their susceptibility in terms of their working environment, front-line healthcare personnel should receive vaccinations before others.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The purpose of this study was to assess the adverse reactions to COVID-19 vaccines among Ethiopian healthcare professionals in 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A facility-based cross-sectional study design was conducted in Addis Ababa Health Facilities, Ethiopia. A total of 290 health professionals who were vaccinated during the study period were involved. Data entry was done by Epidata (version 3.1) and analyzed using SPSS software version 26. Bivariable analysis was conducted and a <jats:italic>p<\/jats:italic> value of less than 0.25 was selected for further multivariable analysis. A <jats:italic>p<\/jats:italic> value of 0.05 was considered statistically significant at a 95% confidence level.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 277 study participants were successfully involved in the study, yielding a response rate of 95.5%. The study participants comprised 123 (44.4%) women and 154 (55.6%) men. The majority of them (202, 72.9%) had received the Oxford AstraZeneca vaccine. Among the 277 study participants, 142 (51.3%) had developed adverse reactions associated with vaccination. Of these, 81 (29.2%) had moderate adverse reactions. Only 2 (0.7%) had developed adverse reactions that led to hospitalization. The most reported short-term adverse reactions were injection site pain (151, 54.5%), headache (114, 41.2%), fever (104, 37.5%), fatigability and tiredness (94, 33.9%), chills (92, 33.2%), muscle pain (79, 28.5%), and decreased sleep quality (34, 12.3%). The multivariable logistic regression showed that the odds of having an adverse reaction were 1.501 times higher among women than men (AOR\u2009=\u20091.501, 95% CI [1.08, 2.754]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion and recommendations<\/jats:title><jats:p>This study revealed that adverse effects following the COVID-19 vaccine were moderate in magnitude and minimal in severity. This study showed that adverse reactions that led to hospitalization were rare. Based on the findings of this study, it is recommended that national, multicenter, prospective, and randomized studies be conducted to assess the independent association of each vaccine.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1187948","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T06:18:35Z","timestamp":1698992315000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Adverse reactions following COVID-19 vaccine among healthcare professionals working in Ethiopia: a facility-based cross-sectional study"],"prefix":"10.3389","volume":"11","author":[{"given":"Adisu","family":"Asefa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitsuh","family":"Derjachew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abebe Muche","family":"Belete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feredegn","family":"Talargia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Molla","family":"Melese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bekalu","family":"Getachew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1\u20132a trial of Ad26. COV2. S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00238-5","article-title":"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study","volume":"397","author":"He","year":"2021","journal-title":"Lancet"},{"year":"2021","author":"Ye","key":"ref4"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.4103\/jfmpc.jfmpc_2370_21","article-title":"Acceptance and adverse effects following COVID-19 vaccination among the health care workers at a health care Centre in the most backward district of India","volume":"11","author":"Sharma","year":"2022","journal-title":"J Fam Med Prim Care"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","article-title":"First month of COVID-19 vaccine safety monitoring\u2014United States, December 14, 2020\u2013January 13, 2021","volume":"70","author":"Gee","year":"2021","journal-title":"Morb Mortal Wkly Rep"},{"year":"2021","key":"ref7"},{"key":"ref8","first-page":"001","article-title":"Knowledge, Awareness and incidence of adverse events following immunization with astrazeneca covid-19 vaccine among healthcare professionals in north central zone of Nigeria","volume":"14","author":"Okezie","year":"2022","journal-title":"Int J Collab Res Intern Med Public Health"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1080\/21645515.2021.1963600","article-title":"Non-life-threatening adverse reactions from COVID-19 vaccine; a cross-sectional study with self-reported symptoms among Ghanaian healthcare workers","volume":"17","author":"Serwaa","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13690-021-00741-x","article-title":"Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021","volume":"79","author":"Konu","year":"2021","journal-title":"Archiv Public Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.2147\/JMDH.S331140","article-title":"COVID-19 vaccine: side effects after the first dose of the Oxford AstraZeneca vaccine among health professionals in low-income country: Ethiopia","volume":"14","author":"Solomon","year":"2021","journal-title":"J Multidiscip Healthc"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"876336","DOI":"10.3389\/fpubh.2022.876336","article-title":"Vaccine side effects following COVID-19 vaccination among the residents of the UAE\u2014an observational study","volume":"10","author":"Ganesan","year":"2022","journal-title":"Front Public Health"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3346\/jkms.2021.36.e115","article-title":"Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea","volume":"36","author":"Bae","year":"2021","journal-title":"J Korean Med Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/POR.S344848","article-title":"Perceptions and experiences of COVID-19 vaccine side-effects among healthcare workers in southern Ethiopia: a cross-sectional study","volume":"12","author":"Zewude","year":"2021","journal-title":"Pragmat Observ Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ijid.2022.03.034","article-title":"Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a systematic review and Meta-analysis","volume":"119","author":"Kim","year":"2022","journal-title":"Int J Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"729251","DOI":"10.3389\/fimmu.2021.729251","article-title":"COVID-19 vaccine-related thrombosis: a systematic review and exploratory analysis","volume":"12","author":"Bilotta","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1187948\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T06:18:42Z","timestamp":1698992322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1187948\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":16,"alternative-id":["10.3389\/fpubh.2023.1187948"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1187948","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"article-number":"1187948"}}